Stock comparison
CorMedix
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CRMD
CorMedix
Market cap
$626.05M
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CRMD | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 72B | LLY |
| Benjamin Graham | 38D | 86A | LLY |
| Philip Fisher |
Side-by-side metrics
| Metric | CRMD | LLY |
|---|---|---|
| Market cap | $626.05M | $1T |
| P/E (TTM) | 3.3x | 36.6x |
| EV/EBIT | 3.7x | 34.1x |
| ROIC (TTM) | 27.59% | 32.06% |
| Gross margin | 85.83% | 83.51% |
| Net margin | 45.25% | 34.98% |
| Revenue CAGR 5y | 5.36% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CRMD leads on
- Revenue CAGR 5y5.36%vs 23.17%+96%
- P/E (TTM)3.3xvs 36.6x+91%
- EV/EBIT3.7xvs 34.1x+89%
- Debt / Equity0.3xvs 1.4x
More like LLY
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.